Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy differences of four low molecular weight heparins for perioperative VTE prevention in major orthopedic surgery
ChiCTR2500101267Phase 4Not yet recruiting
- Sponsor
- People's Hospital of Chuxiong Yi Autonomous Prefecture
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enoxaparin, dalteparin, nadroparin and low molecular weight heparin calcium in venous thromboembolism (VTE) (4 arms), sponsored by People's Hospital of Chuxiong Yi Autonomous Prefecture. Primary endpoint: VTE incidence rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
enoxaparindalteparinnadroparinlow molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2500101267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101267.